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Features of the cervicovaginal 
microenvironment drive cancer 
biomarker signatures in patients 
across cervical carcinogenesis
Paweł Łaniewski1, Haiyan Cui2, Denise J. Roe2, Dominique Barnes3,4, Alison Goulder1, 
Bradley J. Monk3,4,5,6, David L. Greenspan3,4,5, Dana M. Chase2,3,4,5,6 &  
Melissa M. Herbst-Kralovetz  1,2,5
persistent human papillomavirus (HpV) infection is the vital factor driving cervical carcinogenesis; 
however, other features of the local cervicovaginal microenvironment (CVM) may play a critical role in 
development of precancerous cervical dysplasia and progression to invasive cervical carcinoma (ICC). 
Here we investigated relationships between locally secreted cancer biomarkers and features of the local 
CVM to better understand the complex interplay between host, virus and vaginal microbiota (VMB). 
We enrolled women with ICC, high- and low-grade squamous intraepithelial lesions, as well as, HpV-
positive and healthy HpV-negative controls. A broad range of cancer biomarkers was present in the 
local CVM and specifically elevated in ICC patients. The majority of cancer biomarkers were positively 
correlated to other biomarkers and linked to genital inflammation. Several cancer biomarkers were also 
negatively correlated to Lactobacillus abundance and positively correlated with abnormal vaginal pH. 
Finally, a hierarchical clustering analysis of cancer biomarkers and immune mediators revealed three 
patient clusters, which varied in levels of cancer biomarkers, genital inflammation, vaginal pH and VMB 
composition. Specific cancer biomarkers discriminated patients with features of the CVM, such as high 
genital inflammation, elevated vaginal pH and dysbiotic non-Lactobacillus-dominant VMB, that have 
been associated with HpV persistence, dysplasia and progression to ICC.
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, with an estimated 
14.1 million new cases in the United States annually1. More than 200 HPV genotypes have been identified to date 
and over 40 genotypes are tropic to the genital mucosa and spread through sexual contact2. The majority of HPV 
infections are eliminated by the host within a few years. However, HPV infections that evade the immune system 
and are not cleared may lead to serious long-term health consequences. Many anogenital HPV types, defined 
as low-risk types, can cause benign abnormalities, i.e. genital warts. Conversely, high-risk HPV genotypes are 
well-established carcinogenic agents that can cause cervical, vulvar, penile, anal, and oropharyngeal tumors. Of 
these, cervical cancer represents the greatest global health burden, as it is the most common HPV-related cancer, 
with >500,000 new cases annually, and the fourth most common cancer in women3.
Ninety-nine percent of cervical cancers contain high-risk HPV4; however, the majority of high-risk HPV 
infections do not progress to cancer, but instead clear spontaneously. It is well documented that persistent HPV 
infection is the vital factor driving the development of precancerous cervical intraepithelial neoplasia (CIN) and 
progression to invasive cervical carcinoma (ICC)5–10. Several cofactors such as smoking, age of sexual debut, high 
parity, long-term use of contraceptives, hormone treatment and co-infections with sexually transmitted patho-
gens have been shown to be associated with progression of cervical neoplasia among HPV-infected women11–13. 
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In recent years, accumulating evidence suggests that the microbiome might also play a significant role in the 
natural history of HPV infection14–24.
The vaginal microbiota (VMB) in the majority of healthy premenopausal women is dominated by Lactobacillus 
species (Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii or Lactobacillus iners)25–28. 
Lactobacillus spp. protect the host against genital infections through the production of lactic acid, which acidi-
fies the local microenvironment, and by secretion of other antimicrobial compounds28,29. Consequently, women 
with Lactobacillus-dominant (LD) VMB exhibit low vaginal pH (≤4.5), an indicator of homeostasis and vaginal 
health24,29. When dysbiosis occurs, i.e. during bacterial vaginosis (BV), lactobacilli are depleted and replaced 
by a polymicrobial consortium of microaerophilic and anaerobic bacteria (Gardnerella Atopobium, Prevotella, 
Sneathia, Anaerococcus, Peptostreptococcus, Parvimonas, Megasphaera, and bacteria from other genera)24,29.
Recently, numerous epidemiological studies have shown associations between the dysbiotic 
non-Lactobacillus-dominant (NLD) VMB and HPV infection, development of precancerous dysplasia and pro-
gression to cervical cancer14–24,30. BV has been associated with a higher risk of HPV acquisition and decreased 
clearance of HPV16–18. Several reports also revealed that HPV-infected individuals more frequently have 
diverse NLD VMB14,15. Moreover, multiple clinical studies identified bacterial taxa associated with HPV per-
sistence (Atopobium, Mycoplasma hominis, Haemophilus)19,23,31,32 and cervical neoplasia (Sneathia, Atopobium, 
Parvimonas, Fusobacterium, Anaerococcus, Peptostreptococcus)20,21,24. We and others also showed decreased 
Lactobacillus dominance and higher rates of diverse dysbiotic VMB in patients with precancerous lesions and 
cervical cancer, which correlated with increased vaginal pH20,21,24. Notably, one longitudinal study also found an 
association of L. gasseri with HPV clearance19.
To better understand the impact of VMB on the local cervicovaginal microenvironment (CVM), herein we 
examined a broad panel of known circulating cancer biomarkers (i.e. growth and angiogenic factors, hormones, 
pro-inflammatory cytokines/chemokines and others) in cervicovaginal lavages (CVL) collected from patients 
with cervical cancer or cervical dysplasia, as well as, healthy HPV-positive and HPV-negative women without 
neoplasia. Our comprehensive analysis allowed us to identify signatures associated with neoplastic disease and 
the VMB composition. Additionally, by integrating our cancer biomarker, immune mediator, vaginal pH and 
VMB datasets, we were able to reveal patient groups with particular features of CVM that may contribute to 
HPV persistence, development of precancerous lesions and progression to cancer. The presented study further 
investigates CVM features and brings us closer to understanding the complex relationship between the host, local 
microbiome and HPV during cervical carcinogenesis.
Results
patient demographics, HpV status and vaginal pH. A total of 78 premenopausal women were classi-
fied into five groups: healthy HPV-negative controls (Ctrl HPV−; n = 18), HPV-positive controls (Ctrl HPV+; 
n = 11), women diagnosed with low-grade intraepithelial lesions (LSIL; n = 12), high-grade intraepithelial lesions 
(HSIL; n = 27) and ICC (n = 10). Table 1 shows the participant demographics. There was no significant differ-
ence among the groups in terms of age (P = 0.46), body mass index (BMI) (P = 0.97), HPV status (including 
HPV16, HPV18, high-risk and low-risk genotypes distribution) (P > 0.05), HPV risk profile (including infections 
with single or multiple high-risk genotypes as well as mixed infections with high-risk and low-risk genotypes) 
(P > 0.05). Prevalence of 37 HPV genotypes (including 13 high-risk and 24 low-risk genotypes) detected among 
the patient groups is shown in Supplementary Table 1. Forty-seven percent of patients were of Hispanic origin 
and 53% were of non-Hispanic origin. Hispanic ethnicity was not significantly different among the groups, rang-
ing from 28% (5/18) in Ctrl HPV− to 63% (17/27) in HSIL (P = 0.15). Two factors, type of contraception and 
vaginal pH, varied across the groups. The vaginal pH data was associated with the disease severity, as the per-
centage of patients with abnormal pH (defined as >4.5) significantly varied (P = 0.003) and gradually increased 
among the patient groups (Table 1). Ctrl HPV− group had the lowest rate of abnormal pH (50%, 9/18), whereas 
ICC group had the highest rate of abnormal pH (100%, 9/9).
Circulating cancer biomarkers are present in the local cervicovaginal microenvironment. To 
characterize local cancer biomarkers in patients at various stages of cervical neoplasia, we measured 24 can-
cer biomarkers in CVL samples. The levels of 23 cancer biomarkers were in the detectable range; the levels of 
β-human chorionic gonadotropin (β-hCG) were below the detection limit. We found that 13 cancer biomarkers 
were significantly elevated in ICC (P ranging from 0.02 to <0.0001) when compared to Ctrl HPV− (Fig. 1A). 
Functionally, targets that were increased in ICC were comprised of proinflammatory cytokines [interleukin 
(IL)-6, tumor necrosis factor (TNFα)], apoptosis-related proteins [soluble Fas receptor (sFas), soluble Fas ligand 
(sFasL), TNF-related apoptosis-inducing ligand (TRAIL)], hormones (leptin, prolactin), growth and angiogenic 
factors [hepatocyte growth factor (HGF), stem cell factor (SCF), vascular endothelial growth factor (VEGF)] 
and other multi-functional proteins [osteopontin (OPN), cytokeratin fragment (CYFRA) 21-1, α-fetoprotein 
(AFP)]. Only levels of three biomarkers: HGF, OPN, transforming growth factor α (TGF-α) were altered in the 
precancerous groups (Supplementary Fig. S1). Levels of HGF and TGF-α were significantly decreased in HSIL 
(P = 0.001 and <0.05, respectively) and OPN levels were significantly increased in Ctrl HPV+ (P = 0.04) when 
compared to Ctrl HPV−. Additionally, we performed a receiver operating characteristics (ROC) analysis to eval-
uate discriminatory abilities for these cancer biomarkers (Supplementary Fig. S2). Cancer biomarkers with area 
under curve (AUC) values, which indicate both sensitivity and specificity, greater than 0.8 were considered as 
good discriminators and 0.9 as excellent discriminators. The ROC analysis comparing patients with ICC to Ctrl 
HPV− revealed that five tested cancer biomarkers: TNFα, CYFRA 21-1, macrophage migration inhibitory factor 
(MIF), prolactin and SCF had AUC greater than 0.8 (Fig. 1B,C). This analysis demonstrated that these five cancer 
biomarkers, when measured in the CVL samples, can significantly distinguish ICC patients from healthy Ctrl 
HPV−. These novel findings demonstrate that circulating cancer biomarkers that are normally detectable in the 
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plasma/serum can also be found in the local CVM and are specifically elevated in cervical cancer patients, but not 
in patients with precancerous lesions or healthy controls.
Cancer biomarkers are related to cervical carcinoma and linked to genital inflammation and 
microbiota composition. To reduce dimensionality of the data, we applied a principal component analysis 
(PCA) for the measured cancer biomarker levels (Fig. 2). The first two principal components explained 52.0% of 
the variance in the data and were used in our analysis. The analysis revealed that samples from patients with ICC 
significantly separated (P < 0.0001) from samples collected from other patients, including healthy controls as well 
those with precancerous dysplasia (Fig. 2A). Pairwise comparisons demonstrated statistically significant differ-
ences between ICC and Ctrl HPV− (P = 0.0001), ICC and Ctrl HPV+ (P = 0.002), and ICC and LSIL (P = 0.004), 
as well as, ICC and HSIL (P = 0.0001). Analysis of each component separately showed that only the first princi-
pal component, but not the second principal component, was significantly different among the patient groups 
(Fig. 2A). The analysis revealed that expression of cancer biomarkers in the local CVM is related to cervical 
carcinoma.
In our previous report, we showed significant changes in the VMB composition (decrease in Lactobacillus 
dominance) and increased evidence of genital inflammation in patients with ICC24, therefore we included these 
factors in the principal component analysis to determine if these factors were associated with cancer biomarker 
patterns. For Lactobacillus dominance, samples were subdivided into two categories: samples from patients with 
LD microbiota (relative abundance ≥80%)) versus samples from patients with NLD microbiota (relative abun-
dance <80%). For evidence of genital inflammation, samples were subdivided into two groups: samples from 
patients with high inflammatory scores (5–7) and samples from patients with low inflammatory scores (0–4). The 
inflammatory score for each patient was determined previously by assigning one point for each cytokine/chemok-
ine: IL-1α, IL-1β, IL-8, macrophage inflammatory protein (MIP)-1β, MIP-3α, RANTES, and TNFα, when its 
level was in the upper quartile24. The PCA of cancer biomarkers showed that samples also significantly cluster 
according to Lactobacillus dominance (P < 0.0001; Fig. 2B) and inflammatory score (P < 0.0001; Fig. 2C). When 
the first and second principal components were analyzed individually, LD and NLD groups were significantly 
different only in the second principal component (P < 0.001), whereas low (score: 0–4) and high inflammatory 
score (score: 5–7) groups were significantly different in the first principal component (P < 0.0001). The PCA also 
showed that samples did not group into separate clusters according to ethnicity, vaginal pH or BMI (data not 
shown). These data illustrate that cancer biomarker expression is also linked to the level of genital inflammation 
and the VMB composition.
The majority of cancer biomarkers are strongly correlated with other cancer biomarkers.  To 
explore the correlation of each cancer biomarker to other cancer biomarkers in the local CVM, we analyzed 
n
Ctrl HPV− 
(n = 18)
Ctrl HPV+ 
(n = 11)
LSIL 
(n = 12)
HSIL 
(n = 27)
ICC 
(n = 10) P value
Age (mean (SD)) 78 40.38 (6.98) 36.36 (9.53) 35.08 (7.24) 38.29 (8.46) 38.90 (9.09) 0.46
Ethnicity (n (%))
Hispanic 37 5 (27.78) 4 (36.36) 7 (58.33) 17 (62.96) 4 (40.00) 0.15
Non-Hispanic 41 13 (72.72) 7 (63.64) 5 (41.67) 10 (37.04) 6 (60.00)
BMI (n (%))
≤25 25 7 (38.89) 3 (27.27) 4 (33.33) 8 (29.63) 3 (30.00) 0.97
>25 53 11 (61.11) 8 (72.73) 8 (66.67) 19 (70.37) 7 (70.00)
HPV status (n (%))
HPV16 positive 43 9 (81.82) 8 (72.73) 19 (70.37) 7 (70.00) 0.78
HPV18 positive 6 0 (0.00) 1 (9.09) 4 (14.81) 1 (10.00) 0.62
Other high-risk HPV 38 5 (45.55) 10 (83.33) 19 (70.37) 4 (40.00) 0.09
Low-risk HPV 2 0 (0.00) 0 (0.00) 1 (3.70) 1 (10.00) 0.45
HPV risk profile (n (%))
Single high-risk 31 8 (72.73) 3 (25.00) 13 (48.15) 7 (70.00) 0.08
Multiple high-risk 26 3 (27.27) 8 (66.67) 13 (48.15) 2 (20.00) 0.11
High- and low-risk 57 11 (100.00) 11 (91.67) 26 (96.30) 9 (90.00) 0.55
Type of contraception (n (%))
Hormonal 16 2 (20.00) 5 (62.50) 3 (42.86) 2 (11.11) 4 (80.00) 0.03
Non-hormonal 20 3 (30.00) 2 (25.00) 2 (28.57) 12 (66.67) 1 (20.00)
None 12 5 (50.00) 1 (12.50) 2 (28.57) 4 (22,22) 0 (0.00)
Vaginal pH (n (%))
≤4.5 15 9 (50.00) 1 (11.11) 3 (27.27) 2 (7.41) 0 (0.00) 0.003
>4.5 59 9 (50.00) 8 (88.89) 8 (72.73) 25 (92.59) 9 (100.00)
Table 1. Patient demographics. pH data available for 74 individuals; contraception data available for 48 
individuals. P values were calculated using ANOVA for continuous variables and Fisher’s exact test for 
categorical values.
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concentration levels of cancer biomarkers in all tested samples, regardless of patient groups. We computed 
Spearman’s correlation coefficients (ρ) for all pairs of cancer biomarkers (Fig. 3A and Supplementary Fig. S3). The 
analysis showed that most cancer biomarkers in the CVL samples were positively correlated, which is evidenced 
Figure 1. Cancer biomarkers are present in the cervicovaginal microenvironment and specifically elevated in 
cervical cancer patients. The level of cancer biomarkers in cervicovaginal lavages of ICC patients is compared 
to Ctrl HPV− (A). Box-and-whiskers plots represent the median and interquartile range with whiskers ranging 
between the 10th and 90th percentiles; dots indicate outliers. P values were calculated using linear mixed effects 
models where group was the fixed effect and replicate was the random effect with Tukey adjustment. *P < 0.05; 
**P < 0.01; ***P < 0.001; ***P < 0.0001. The receiver operating characteristics (ROC) analysis comparing 
ICC to Ctrl HPV− groups. Cancer biomarkers with area under curve (AUC) values greater than 0.8 serve as 
good discriminators for ICC (B). ROC curves indicating specificity and sensitivity of cancer biomarkers with 
AUC > 0.8 are depicted (C).
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by the majority of red-shaded squares of the heat map [only coefficients that were significant (P < 0.05) are 
depicted on the heat map] (Fig. 3A). We noted that after excluding self-to-self correlation, 40.3% of all pairs of 
cancer biomarkers (102/253) exhibited a positive correlation (adjusted P < 0.05). Hierarchical clustering analysis 
of the correlation matrix also revealed two major groups of cancer biomarkers strongly correlated to each other. 
The first group consisted of SCF, leptin, TNFα, TRAIL, basic fibroblast growth factor (FGF2), MIF, sFasL, prolac-
tin and OPN and the second group consisted of IL-6, VEGF, HGF, CYFRA 21-1, sFas, TGF-α, carcinoma antigen 
(CA) 15-3, CA 125 and human epididymis protein 4 (HE4). In the first cluster, 100% of pairs of cancer biomarkers 
(36/36) exhibited positive correlation (adjusted P < 0.05) with the highest correlations between FGF2 and leptin 
(ρ = 0.84, P < 0.0001), FGF2 and TRAIL (ρ = 0.80, P < 0.0001) and leptin and TRAIL (ρ = 0.77, P < 0.0001). In the 
other cluster, 71.1% of pairs of cancer biomarkers (32/45) exhibited positive correlation (P < 0.05) with the high-
est correlations between HGF and VEGF (ρ = 0.84 P < 0.0001), HGF and sFas (ρ = 0.79, P < 0.0001) and IL-6 and 
VEGF (ρ = 0.76, P < 0.0001). The analysis showed that women with a high concentration of one cancer biomarker 
were relatively likely to have high concentrations of other cancer biomarkers.
Cancer biomarkers are correlated to genital inflammation, vaginal pH and Lactobacillus abundance. 
Since the PCA analyses showed that genital inflammation and vaginal microbiota composition impact cancer 
biomarker signatures, we also examined correlations between the levels of cancer biomarkers (in all tested sam-
ples regardless of patient groups) and inflammatory scores, Lactobacillus abundance or vaginal pH (Fig. 3B and 
Figure 2. Cancer biomarkers cluster according to disease severity, vaginal microbiota composition and level of 
genital inflammation. Principal component analysis of all cancer biomarker data displayed along the first two 
principal components, with each point representing a single sample colored according to patient group (A), 
Lactobacillus dominance (defined as ≥80% relative abundance) (B), or inflammatory score (low inflammatory 
score: 0–4; high inflammatory score: 5–7) (C). Box-and-whiskers plots shown along each principal component 
axis represent the median and interquartile range with whiskers ranging between the 10th and 90th percentiles 
and indicate the distribution of samples along the given axis. P values were calculated using MANOVA.
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Supplementary Fig. S4). The analysis revealed that 19 out of 23 cancer biomarkers (82.61%) exhibited signifi-
cant positive correlation to inflammatory scores (adjusted P < 0.05). Furthermore, nine cancer biomarkers: MIF, 
TNFα, sFasL, TRAIL, FGF2, SCF, prolactin and OPN, were negatively correlated to Lactobacillus abundance and 
positively correlated to levels of vaginal pH. Interestingly, we also identified that an antimicrobial peptide, HE4, 
to be positively correlated to Lactobacillus abundance and negatively correlated to vaginal pH. Additionally, we 
examined associations among secreted cancer biomarkers, patient groups, and Lactobacillus dominance (relative 
abundance ≥80%) using mixed effects model (Supplementary Fig. S5). As other factors might also contribute to 
changes in the microbiota composition, we controlled our data for age, BMI and ethnicity. Following adjustment 
for covariates, only three cancer biomarkers, CYFRA 21-1, SCF and OPN, were positively associated with ICC in 
patients with LD or NLD microbiota, whereas eleven cancer biomarkers, IL-6, TNFα, TRAIL, sFas, sFasL, FGF2, 
HGF, VEGF, prolactin, leptin, and AFP were positively associated with ICC only in patients with NLD microbiota 
when compared to Ctrl HPV−. The analysis further confirmed that associations of cancer biomarkers with inva-
sive carcinoma depend on the VMB composition, specifically non-Lactobacillus dominance.
Hierarchical clustering of cancer biomarkers reveals high- and low-risk clusters associated with 
features of cervicovaginal microenvironment. To investigate the complex interplay between local 
cancer biomarkers, cytokine/chemokines and patient-specific factors we performed unsupervised hierarchical 
clustering analysis of cancer biomarker data together with immune mediator data. The heat map and dendro-
gram revealed three distinct clusters of patients (Fig. 4A). To characterize these clusters, we plotted metadata 
available for each patient (patient group/disease severity, ethnicity, vaginal pH, Lactobacillus dominance and 
inflammatory score) above the heat map and analyzed statistical differences in those patient-specific factors 
among three clusters. We found that distribution of patient groups, rates of Lactobacillus dominance, levels of 
vaginal pH and inflammatory scores were significantly different among the clusters (P < 0.001). The percentage of 
patients of Hispanic origin, compared to non-Hispanic origin, did not vary among the clusters (P = 0.75). Based 
on the characteristics described below, we designated the patient clusters as associated with cancer, associated 
with high VMB diversity and high inflammation and associated with low VMB diversity and low inflammation. 
First, the distribution of patient groups significantly differed among the three clusters (P = 0.0002) (Fig. 4B). The 
cancer-associated cluster had the highest rate of patients with ICC (75.00%), whereas the high and low diversity/
inflammation clusters consisted of only 13% and 2% patients with ICC, respectively. Interestingly, the high and 
low diversity/inflammation clusters did not significantly vary based on disease severity (P = 0.15). However, rates 
of patients with dysbiotic NLD microbiota (defined as <80% relative abundance of Lactobacillus spp.) were sig-
nificantly increased in the cancer-associated cluster (87.50%; P = 0.02), as well as, the high diversity/inflammation 
cluster (69.57%; P = 0.01) when compared to the low diversity/inflammation cluster (38.87%). Furthermore, for 
Figure 3. Cancer biomarkers are strongly correlated to other cancer biomarkers, genital inflammation, as 
well as, vaginal pH and Lactobacillus abundance. Correlation of cancer biomarkers to other cancer biomarkers 
(A), or Lactobacillus abundance, vaginal pH and inflammatory scores (B) in the cervicovaginal lavages among 
all the patients are depicted. Correlation coefficients (ρ) were calculated using Spearman’s rank correlation 
analysis. Hierarchical clustering of correlation coefficients was performed using CIMminer based on Euclidean 
distance and average linkage cluster algorithm. A bar on each dendrogram indicates separate clusters of cancer 
biomarkers. Only correlation coefficients that were significant (P < 0.05) are displayed on the heat map. Red- 
and blue-shaded squares indicate positive and negative correlations, respectively. All correlation coefficient 
values can be found in Supplementary Figs S3 and S4.
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Figure 4. Hierarchical clustering analysis reveals three distinct patient clusters: cancer-associated, high 
diversity/inflammation and low diversity/inflammation. A heat map reflects relative levels of cancer biomarkers 
and immune mediators in the cervicovaginal lavages across all the samples. Data were mean centered and 
variance scaled along each row before clustering. Hierarchical clustering was performed using CIMminer based 
on Euclidean distance between rows and columns and the average linkage cluster algorithm. Red- and blue-
shaded squares indicate increased or decreased levels compared to the mean value for each target, respectively. 
Patient clusters, patient groups, ethnicity, vaginal pH, Lactobacillus dominance, pre-dominant Lactobacillus 
species and inflammation score are also shown across above the heat map (A). Distribution of patient groups 
(B), Lactobacillus dominance (C) and levels of vaginal pH (D) and inflammatory scores (E) were significantly 
different among the clusters (cancer: cancer-associated cluster; high d/i: high diversity/inflammation cluster; 
low h/i: low diversity/inflammation cluster). P values were calculated using Kruskal-Wallis or Fisher’s exact test.
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the patients with LD microbiota, the predominant Lactobacillus species also varied among the clusters (P < 0.05). 
Vaginal health-associated L. crispatus commonly predominated patients’ microbiota in the low diversity/inflam-
mation cluster (32.61% of patients), but not in the high diversity/inflammation or cancer-associated clusters 
(4.35% and 0.00%, respectively), whereas intermediate L. iners were found among all patient clusters. Mean pH 
values were also significantly different among the clusters (P = 0.0002) (Fig. 4D). Vaginal pH data were available 
for 74/78 women. Vaginal pH was significantly elevated in the cancer-associated cluster (mean ± SD 6.85 ± 0.62; 
P = 0.001), and high diversity/inflammation cluster (mean ± SD 5.91 ± 1.01) compared to the low diversity/
inflammation cluster (mean ± SD 5.26 ± 0.78; P = 0.02). Similarly, inflammatory score, which is an evidence of 
genital inflammation, varied significantly among the clusters (P < 0.0001) (Fig. 4E). The cancer-associated cluster 
had the highest inflammatory score (mean ± SD 4.00 ± 2.67), whereas the low diversity/inflammation cluster 
had the lowest score (mean ± SD 0.57 ± 0.92), which was statistically significant (P = 0.0002). The high diversity/
inflammation cluster also had a significantly elevated inflammatory score (mean ± SD 3.42 ± 1.70) compared to 
the low diversity/inflammation cluster (P < 0.0001).
We also compared the levels of tested cancer biomarkers in CVL samples among the three clusters 
(Supplementary Fig. S6). We found that 15 cancer biomarkers were significantly elevated in both high diversity/
inflammation and cancer-associated clusters (P ranging from 0.03 to <0.0001) when compared to the low diver-
sity/inflammation cluster (Fig. 5A). Notably, these cancer biomarkers functionally comprised of several cytokines 
(IL-6, MIF, TGF-α, TNFα), apoptosis-related proteins (sFas, sFasL, TRAIL), growth and angiogenic factors (FGF2, 
HGF, SCF, VEGF), hormones (leptin, prolactin) and other biomarkers (AFP, OPN), but not carcinoma antigens. 
Seven of these biomarkers (TNFα, sFasL, SCF, VEGF, leptin, prolactin, OPN) were also significantly elevated in the 
cancer-associated cluster compared to the high diversity/inflammation cluster (P ranging from 0.02 to <0.0001) 
(Fig. 5A). Furthermore, we performed the ROC analysis comparing the high and low diversity/inflammation clus-
ters (Supplementary Fig. S7). The analysis revealed that 11 targets have good discriminatory potential (AUC > 0.8) 
between the high and low diversity/inflammation clusters (Fig. 5B). The biomarkers with the highest sensitivity and 
specificity were CYFRA 21-1, TNFα, TRAIL, leptin and sFasL (AUC 0.87–0.89, P < 0.0001) (Fig. 5C). Interestingly, 
a subset of identified cancer biomarkers (TNFα, sFasL, TRAIL, prolactin, FGF2, SCF, OPN), which were identified 
in the high diversity/inflammation cluster, were also correlated with Lactobacillus abundance, vaginal pH and genital 
inflammation (Fig. 3B) and were elevated in the ICC group (Fig. 1A).
Overall, these data allowed us to stratify patients into three groups: (i) the cancer-associated group, (ii) the 
high diversity/inflammation group, and (iii) the low diversity/inflammation group. Both the cancer-associated 
group and the high diversity/inflammation group were characterized by elevated levels of locally secreted cancer 
biomarkers, low rates of Lactobacillus dominance, high vaginal pH and high genital inflammation, all features 
associated with HPV persistence and hallmarks of cancer14,15,19–21,23,24,33,34. In contrast, the low diversity/inflam-
mation group was characterized by a high abundance of Lactobacillus, lower vaginal pH and low genital inflam-
mation, all features associated with vaginal health19,33.
Discussion
Persistent infection with high-risk HPV is a well-established risk factor for development of ICC and its precancer-
ous precursor, CIN. However, the majority of HPV infections are cleared by the host. Thus, other features of the 
local CVM (e.g. microbiome, pH, host immune mediators, environmental factors) may play a critical role in HPV 
persistence and impact hallmarks of cancer. In this report, we investigated relationships between locally secreted 
cancer biomarkers, VMB, vaginal pH, genital inflammation, and the severity of cervical neoplasia to determine 
features of the CVM that may contribute to HPV persistence, development of dysplasia and progression to cancer.
To our knowledge, this is the first report comprehensively examining the level of circulating cancer biomark-
ers in the local CVM. Herein, we took an unbiased approach and screened a broad range of proteins that are 
involved in neoplastic transformation. We determined levels of 24 targets in CVL samples collected from patients 
with ICC, HSIL, and LSIL, defined by histology, as well as, HPV-positive and HPV-negative women without neo-
plasia. These biomarkers are proteins that play a vital role during tumor development and progression, but also 
exhibit physiological functions (apoptosis-related proteins, growth factors, etc.) during homeostasis.
Our analysis revealed elevated levels of several biomarkers, including proinflammatory cytokines (IL-6, TNFα), 
apoptosis-related proteins (sFas, sFasL, TRAIL), hormones (leptin, prolactin), growth and angiogenesis factors 
(HGF, SCF, VEGF), cytokeratins (CYFRA 21-1), and others (AFP, OPN), only in cervical cancer patients, but 
not in other patient groups. Moreover, the biomarker discovery analysis showed that several of these biomarkers 
(TNFα, CYFRA 21-1, MIF, prolactin and SCF) exhibit high sensitivity and specificity for ICC when measured in 
CVL samples. A very limited number of studies have examined cancer biomarkers in cervicovaginal secretions 
[IL-6, IL-8, CA 125, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC-Ag)]35–37, 
although numerous reports showed that several of these biomarkers were significantly elevated in serum and/
or biopsies collected from patients with invasive cervical carcinoma. Recent studies have also utilized cellular 
microRNA, single nucleotide polymorphism and DNA methylation patterns or gene/protein expression profiles 
as potential detection and prognosis markers38–41. Our data confirmed findings from a previous study reporting 
elevated levels of IL-6 in CVL of cervical cancer patients when compared to healthy controls or patients with 
cervical dysplasia35. Similar to our CVL findings, other researchers found significantly increased levels of IL-6, 
VEGF, HGF and OPN in both cancer patients’ sera and cancerous tissues42–49. Other immunohistochemical stud-
ies also showed overexpression of FasL, TRAIL and leptin in cancerous tissues50, which was consistent with our 
CVL findings. In contrast to our results, a study by McDicken et al. showed elevated levels of CEA in CVL of 
patients with CIN and ICC compared to controls36. However, another study suggested that CEA is a normal con-
stituent of vaginal fluid, with levels that may be affected, not only by cancer, but also pregnancy or genital inflam-
mation37. Ascencio-Cedillo et al. also showed that there was no difference in expression of prolactin in cancer 
tissue or serum when compared to samples collected from healthy individuals51, which we found to be elevated 
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Figure 5. Several cancer biomarkers strongly discriminate cancer-associated, high diversity/inflammation 
and low diversity/inflammation cluster groups, which differ in vaginal pH, microbiota composition and genital 
inflammation. The level of cancer biomarkers in cervicovaginal lavages among the three cluster groups from the 
hierarchical clustering analysis (A). Box-and-whiskers plots represent the median and interquartile range with 
whiskers ranging between the 10th and 90th percentiles; dots indicate outliers. P values were calculated using 
linear mixed effects models where group was the fixed effect and replicate was the random effect with Tukey 
adjustment. *P < 0.05; **P < 0.01; ***P < 0.001; ***P < 0.0001. The receiver operating characteristics (ROC) 
analysis comparing the high diversity/inflammation (d/i) cluster to the low diversity/inflammation (d/i) cluster. 
Cancer biomarkers with area under curve (AUC) values greater than 0.8 serve as good discriminators for the 
high diversity/inflammation cluster group (B). ROC curves indicating specificity and sensitivity of cancer 
biomarkers with AUC > 0.85 are depicted (C).
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in CVL. Other serum biomarkers, which have been previously used for cervical cancer diagnosis and prognosis, 
included SCC-Ag, CA 125, CA 15-3, CEA and CYFRA 21-141,52. We did not test SCC-Ag in this study, nor did 
we observe elevated levels of CA 125 or CA 15-3 in CVL in patients with ICC. Herein, we confirmed that a broad 
range of circulating cancer biomarkers are present in the local CVM and specifically elevated in women with ICC. 
It is important to note that local and systemic levels of these proteins may significantly differ, which might reflect 
their distinct functions during homeostasis and during neoplastic transformation. Specificity of these proteins as 
biomarkers may also be dependent on protein localization.
In our study, we also found that the majority of cancer biomarkers were highly correlated to other cancer bio-
markers, which indicates that these proteins form biological integration networks in the local CVM. Using corre-
lation and hierarchical clustering analyses, we identified two groups of cancer biomarkers highly correlated with 
each other. The first group was comprised of IL-6, VEGF, HGF, CYFRA 21-1, sFas, TGF-α, CA 15-3, CA 125, and 
HE4, with the highest correlations between HGF, VEGF and IL-6. It is well documented that IL-6 plays a central 
role in tumor progression due its ability to promote cell proliferation and inhibit apoptosis53. Both in vitro and in 
vivo studies demonstrated that high local IL-6 levels can stimulate VEGF production and promote tumor angio-
genesis, and development of cervical cancer47,54. In our study we observed that patients concomitantly exhibited 
high levels of IL-6 and VEGF in CVL. Moreover, we also observed a strong positive correlation of VEGF and 
HGF, which indicates that HGF plays an important role during cervical carcinogenesis. Studies have reported 
that c-Met activation by HGF stimulates multiple signal transduction pathways, which results in cell proliferation, 
motility, tumor progression, and metastasis55. The other cluster consisted of leptin, FGF2, TNFα, MIF, TRAIL, 
SCF, sFasL, prolactin, and OPN, with the highest correlation between leptin and FGF2. Leptin, which is one of the 
main adipokines secreted by adipose tissue, has been implicated in the progression of multiple cancers through 
activation of the Janus kinase 2 (JAK)-signaling transducer and activator of transcription (STAT)-3 signaling 
pathway56. Leptin regulates cell turnover and facilitates the progression of cervical cancer57. FGF2 is similar to 
VEGF and acts as a potent angiogenic growth factor58. A study by Cao et al. has shown that leptin induces vascu-
lar permeability and acts synergistically with VEGF and FGF2 to promote angiogenesis59.
In this report, we integrated multiple datasets (immune mediators, genital inflammation, VMB composi-
tion, and vaginal pH) with the cancer biomarker data to perform exploratory data analysis using unsupervised 
methods. Using data reduction analyses we revealed that local cancer biomarker secretion is associated with 
both genital inflammation and the VMB composition. Our analyses revealed that the levels of majority of cancer 
biomarkers correlated with genital inflammation. We also identified a subset of cancer biomarkers that strongly 
correlated, not only with genital inflammation, but also with Lactobacillus abundance and vaginal pH, suggesting 
that these features of CVM may play a crucial role during neoplastic transformation. The data integration allowed 
us to stratify patients into distinct groups characterized by CVM features, such as high VMB diversity and inflam-
mation, that may promote HPV persistence and cancer/dysplasia progression. As expected, the hierarchical clus-
tering analysis of cancer biomarkers and immune mediators showed that the majority of cancer patients formed 
a separate cluster, that we assigned the “cancer-associated group”. However, the hierarchical clustering analysis 
revealed little stratification of patients based on either the severity of precancerous lesions (HSIL, LSIL) or HPV 
status (HPV-positive and HPV-negative controls) in the other two clusters. Instead, we observed two patient 
clusters, assigned as “high diversity/inflammation” and “low diversity/inflammation” groups, based on features 
of the CVM (genital inflammation, level of vaginal pH and the VMB composition). The cancer-associated and 
high-diversity/inflammation groups were both characterized by low levels of Lactobacillus dominance, high vagi-
nal pH and high genital inflammation and elevated levels of cancer biomarkers, known to be associated with HPV 
persistence, development of dysplasia and progression to cancer14,15,19–21,23,24,33,34. In contrast, the low diversity/
inflammation group was characterized by high levels of Lactobacillus dominance, lower vaginal pH, low genital 
inflammation, and low levels of cancer biomarkers, all features associated with vaginal health19,33. Remarkably, 
several cancer biomarkers (TNFα, sFasL, TRAIL, prolactin, FGF2, SCF, OPN), which were elevated in the 
cancer-associated and high diversity/inflammation clusters when compared to the low diversity/inflammation 
cluster, were also significantly and negatively correlated with Lactobacillus abundance and positively correlated 
with abnormal vaginal pH and genital inflammation. Furthermore, a subset of cancer biomarkers (CYFRA 21-1, 
TNFα, TRAIL, leptin and sFasL) strongly discriminated the high and low diversity/inflammation cluster groups. 
The role of these proteins in cervical carcinogenesis warrants further investigation, particularly in the context 
of vaginal microbiome and/or chronic inflammation. Future studies may investigate the potential use of these 
proteins as markers for disease progression and prognosis of therapeutic outcomes.
In our previous report, we showed that patients with cervical cancer exhibit an increased level of genital 
inflammation24. We hypothesize that local chronic inflammation, a hallmark of cancer, may suppress anti-tumor 
immunity and favor tumor progression. Numerous studies have demonstrated that development of HPV-induced 
cervical cancer is preceded by chronic inflammation53. However, in the majority of reports, genital inflammation 
has been due to the presence of concurrent infection with other sexually transmitted pathogens, including her-
pes simplex virus 2 and Chlamydia trachomatis, or other non-specific infections, including BV16–18,60–62. Recent 
studies have revealed that in women without other sexually transmitted infections, HPV infection or clearance is 
not associated with genital inflammation, but rather the VMB composition60,63. We and others also have shown 
association between the dysbiotic NLD VMB and HPV infection and the severity of cervical neoplasia14–21,23,24,30. 
Abnormal vaginal pH, which correlates with dysbiotic VMB composition, has been also associated with cervical 
neoplasia24. These microenvironmental factors, such as, genital inflammation, abnormal vaginal pH and diverse 
NLD VMB, coupled with increased levels of cancer biomarkers, may favor HPV persistence in the local microen-
vironment and consequently increase the risk of neoplastic disease. Alternatively, the collective action of these 
conditions, including infection with high-risk HPV, may directly impact hallmarks of cancer (cell proliferation, 
evasion of apoptosis, senescence, DNA mutation and methylation, and angiogenesis), contributing to develop-
ment of precancerous lesions and progression to cancer.
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The limitations of our study include a modest sample size, the lack of specific sexual behavior (i.e. number of 
sexual partners or age of sexual debut), smoking history data and a cross-sectional study design, showing asso-
ciations, not causation. In the future, a larger cohort and longitudinal clinical studies will be needed to extend 
our findings for potential clinical utility. Moreover, mechanistic studies using in vitro and in vivo models, will be 
required to fully understand the complex relationships in the CVM between HPV, VMB, genital inflammation 
and development/progression of neoplastic disease.
In conclusion, we showed that a broad range of circulating cancer biomarkers is present in the local CVM and 
identified several cancer biomarkers that were specifically elevated in cervical cancer patients. We also revealed 
that the majority of cancer biomarkers exist concomitantly, which suggests that these proteins form biological 
interaction networks in the local microenvironment. Furthermore, we demonstrated that expression of can-
cer biomarkers is correlated not only with genital inflammation, but also vaginal microbiota composition (i.e. 
Lactobacillus abundance) and vaginal pH. By integrating our cancer biomarker, immune mediator, vaginal pH, 
and VMB datasets, we revealed three patient clusters: cancer associated, high diversity/inflammation and low 
diversity/inflammation. Finally, we identified several cancer biomarkers that could further delineate patients with 
dysbiotic VMB and a high level of genital inflammation from patients with Lactobacillus-dominant VMB and a 
low level of genital inflammation, which may be valuable predictors for HPV persistence, developing dysplasia 
and progressing to invasive carcinoma.
Methods
study population. Patients were recruited at three clinical sites located in Phoenix, AZ: St. Joseph’s Hospital 
and Medical Center, University of Arizona Cancer Center and Maricopa Integrated Health Systems. All patients 
provided informed written consent and all research and related activities involving human subjects were approved 
by the Institutional Review Boards at Dignity Health St. Joseph’s Hospital and Medical Center, University of 
Arizona, and Maricopa Integrated Health Systems and performed in accordance with federal guidelines and 
regulations and the Declaration of Helsinki.
Samples collected from 78 premenopausal, non-pregnant, women diagnosed with ICC (n = 10), HSIL (n = 27) 
and LSIL (n = 12), as well as, healthy Ctrl HPV+ (n = 11) and Ctrl HPV− (n = 18) were included in this study. 
Classification of patients into the five groups and exclusion criteria were described previously24. Briefly, histology 
of colposcopy-directed biopsy samples was used to classify patients into groups. If histology was not available (i.e. 
for healthy Ctrl HPV+ and Ctrl HPV−), cytology was used for classification. Exclusion criteria included: cur-
rently menstruating; currently on antibiotics, antifungals or antivirals or within the previous three months; cur-
rent vaginal infection (including BV), vulvar infection, urinary tract infection or sexually transmitted infection 
(chlamydia, gonorrhea, trichomoniasis, genital herpes, human immunodeficiency virus) or within the previous 
three weeks; unusual or foul-smelling vaginal discharge; use of douching substances, vaginal applied medications 
and suppositories, feminine deodorant sprays, vaginal lubricants within 48 hours prior the visit; any skin condi-
tion in the genital area interfering with the study; sexual intercourse less than 48 hours prior the visit; type I or 
type II diabetes; hepatitis.
Sample collection and processing, HPV genotyping, 16S rRNA sequencing, multiplex analysis 
of immune mediators and genital inflammatory score system.  Collection and processing of vaginal 
swabs, vaginal pH and CVL samples were described previously24. Briefly, mid vaginal swabs were collected by a phy-
sician using the eSwab collection system with Amies transport medium (COPAN, Diagnostics, Murrieta, CA); vagi-
nal pH was measured using nitrazine paper; CVL were collected using 10 ml of sterile 0.9% saline solution. Collected 
samples were immediately placed on ice and frozen at −80 °C, thawed on ice and aliquoted to avoid multiple freeze/
thaw cycles and stored at −80 °C. DNA was extracted from vaginal swabs using the PowerSoil DNA Isolation Kit 
(MO BIO Laboratories, Carlsbad). HPV genotyping and 16S rRNA sequencing were performed using DNA samples 
extracted from vaginal swabs using the Linear Array HPV Genotyping Test (Roche, Indianapolis, IN) and the MiSeq 
Platform (Illumina, San Diego, CA), respectively, as detailed previously24. Levels of 22 cytokines and chemokines 
were determined in CVL aliquots using multiplex cytometric bead arrays or enzyme-linked immunosorbent assays 
as described previously24. The genital inflammatory score system used in this study was described previously24. 
Briefly, levels of seven cytokines (IL-1α, IL-1β, IL-8, MIP-1β, MIP-3α, RANTES, and TNFα) were used to determine 
inflammatory scores; patients were assigned one point for each mediator when the level was in the upper quartile. 
Genital inflammation was defined as having at least 5/7 of the cytokines in the upper quartile.
Measurement of cancer biomarkers. Levels of 24 cancer biomarkers: AFP, CA 15-3, CA 19-9, CA 125, 
CEA, CYFRA 21-1, sFas, sFasL, FGF2, β-hCG, HE4, HGF, IL-6, IL-8, leptin, MIF, OPN, prolactin, total pros-
tate specific antigen (PSA), SCF, TGF-α, TNFα, TRAIL and VEGF were determined in CVL aliquots using the 
Milliplex MAP Human Circulating Cancer Biomarker Magnetic Bead Panel (Millipore, Billerica, MA) in accord-
ance with the manufacturer’s protocol. A four-parameter logistic regression curve fit was used to determine the 
concentration. All samples were assayed in duplicate. The concentration values above the detection limit were 
substituted with the maximum observation values of the target and values below the detection limit were substi-
tuted with 0.5 of the minimum detectable concentration provided in manufacturer’s instructions. The log trans-
formation was applied to normalize the data.
Receiver operating characteristics analysis. The ROC analysis was performed to identify cancer biomark-
ers that discriminate appropriate patient groups. The strength of discriminators was measured with area under the 
curve (AUC) values. Cancer biomarkers with AUC greater than 0.8 or 0.9 were considered as good or excellent dis-
criminators, respectively. The ROC analysis was performed using GraphPad Prism (version 5.0) software.
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principal component analysis. The PCA was performed to reduce the observed variables into a smaller 
number of principal components (artificial variables) that will account for most of the variance in the observed 
variables. For the first two components, the difference among groups was assessed using the multivariate analysis 
of variance (MANOVA) model. If the overall difference was significant (P < 0.05), pairwise comparisons with 
Tukey adjustment were performed. The statistical differences for individual components were assessed using an 
analysis of variance (ANOVA) model.
Correlation analysis. The Spearman’s rank correlation analysis was performed to investigate association of 
cancer biomarkers. A correlation matrix was computed using Spearman’s rank correlation coefficients (ρ) with P 
values, and graphically presented as a heat map. A P < 0.05 was considered significant.
Mixed effects modeling.  Linear mixed effects models were used to evaluate associations of cancer bio-
markers with patient groups, adjusted for the random effect of replicates. The β-coefficient and standard error 
were estimated to show the direction of the association. If the overall difference was significant (P < 0.05), pair-
wise comparisons were performed with Tukey adjustment. Comparisons were adjusted for BMI, age and eth-
nicity in the linear mixed effects models by including these variables as predictors in the models, in addition to 
indicators for the patient groups (with Ctrl HPV− as the reference group). The β-coefficients therefore represent 
the expected change in each immune mediator for that patient group relative to Ctrl HPV− for women with the 
same values of the clinical covariates. Preliminary analyses demonstrated that there were statistically significant 
interactions between Lactobacillus dominance and the patient groups on the levels of the cancer biomarkers 
(P < 0.05). For these cancer biomarkers, comparison between the groups was performed separately for patients 
with LD microbiota and NLD microbiota.
Hierarchical clustering analysis. The hierarchical clustering analysis was performed to show relationships 
between cancer biomarkers, cytokine/chemokine levels and metadata available for each patient, i.e. ethnicity, 
vaginal pH, Lactobacillus dominance, inflammatory scores. Prior to clustering, log-transformed concentration 
levels for each cytokine/chemokine and cancer biomarker were mean centered and then variance was scaled. 
Hierarchical clustering was performed using CIMminer based on Euclidean distance between rows and columns 
and average linkage cluster algorithm64.
other statistical analyses. Statistical differences in the demographic variables, HPV status and risk profile, 
and vaginal pH between patient groups were tested using ANOVA for continuous variables and Fisher’s exact test 
for categorical variables. Following the hierarchical clustering analysis, statistical differences in patient groups, 
Lactobacillus dominance, level of vaginal pH or inflammatory scores were tested using Kruskal-Wallis or Fisher’s 
exact test. All statistical analyses were performed using SAS 9.4.
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